Hong Kong/China M&A/Events

Hong Kong/China M&A/Events

TCM (570 HK): We've Been Here Before

Quiddity Research's avatar
Quiddity Research
Feb 08, 2024
∙ Paid
Share
  • China Traditional Chinese Medicine (570 HK) ("TCM") is the traditional Chinese medicine arm of SASAC-managed China National Pharmaceutical Group Corporation (CNPGC), one of the largest healthcare groups in China.

  • By my reckoning, TCM has fielded three Offers in the past decade, all from Sinopharm Hongkong, an indirect wholly-owned subsidiary of CNPGC and TCM’s major shareholder.

  • TCM was suspended "pursuant to the Code on Takeovers and Mergers" earlier today. The Real McCoy? A no-deal again from CNPGC/Sinopharm? And why didn't the last Offers complete?

Keep reading with a 7-day free trial

Subscribe to Hong Kong/China M&A/Events to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Quiddity Investment Advisors
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture